Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Journal article
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
Accelerating HIV vaccine development through meaningful engagement of local scientists and communities.
Journal article
Chinyenze K. et al, (2023), Curr Opin HIV AIDS, 18, 284 - 289
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study
Journal article
Kimotho J. et al, (2023), Wellcome Open Research, 8, 350 - 350
Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro.
Journal article
Nyagwange J. et al, (2023), Int J Infect Dis, 127, 11 - 16
Exposure to common infections may shape basal immunity and potentially HIV-1 acquisition amongst a high-risk population in Coastal Kenya.
Journal article
Fwambah L. et al, (2023), Front Immunol, 14
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Journal article
Hamaluba M. et al, (2023), Wellcome open research, 8
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Journal article
Hamaluba M. et al, (2023), Wellcome Open Res, 8
Assessment of a diverse panel of transmitted/founder HIV-1 infectious molecular clones in a luciferase based CD8 T-cell mediated viral inhibition assay.
Journal article
Fernandez N. et al, (2022), Front Immunol, 13